Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes

11-Sep-2009 - Israel

Andromeda Biotech Ltd. announced that it has completed patient recruitment in its’ current Phase III study using DiaPep277 for the treatment of Type 1 diabetes.

The current clinical study includes 456 patients and is being conducted at 40 medical centers in Europe, South Africa, and Israel. Patients recruited to the study include young adults (16-45 years old) with residual insulin secreting cells. In the double blind, placebo controlled study; patients are treated once every three months with 1 mg dose of the drug or with placebo for a period of two years. The primary outcome of the study is the ability of DiaPep277 to maintain insulin secretion. Results of this trial are expected at the end of 2011.

“This is an important milestone for intervention therapy studies in Type 1 diabetes and we look forward to the conclusion of this study,” stated Prof. Itamar Raz, Head of the Diabetes Unit at Hadassah University Hospital who chairs the study Steering Committee. “We strongly believe that DiaPep277 will provide hope to patients with a challenging disease such as Type 1 diabetes.”

DiaPep277 is a unique peptide of 24 amino acids derived from the sequence of the human heat shock protein 60 (Hsp60). The peptide acts by modulating the immune system, preventing the destruction of pancreatic cells that secrete insulin and preserving their natural function. Treatment of type 1 diabetes patients with DiaPep277 may have several medical benefits including slowing the deterioration of the disease, improved metabolic control, reduction of daily insulin dose requirements and reduction of diabetic complications.

https://www.bionity.com/en/news/106136/andromeda-biotech-successfully-completes-patient-recruitment-in-phase-iii-trials-for-diapep277-for-type-1-diabetes.html